Literature DB >> 7603756

The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhea.

J W Tapsall1, E A Phillips.   

Abstract

One hundred and thirty seven consecutive isolates of Neisseria gonorrhoeae and a further 36 selected gonococci with either chromosomal (CMRNG) or plasmid mediated (PPNG) resistance to penicillin, all cultured in Sydney in 1993, were found to be sensitive to cefpodoxime, an oral third generation cephalosporin antibiotic (MIC range < 0.001-0.25 mg/L). All isolates were also sensitive to ceftriaxone and spectinomycin. Six gonococci showed high level resistance to tetracycline (TRNG, MIC = 32 mg/L) and 12 had decreased susceptibility to quinolone antibiotics (MIC range 0.06-0.5 mg/L). The MIC50 and MIC90 for both cefpodoxime and ceftriaxone were highest amongst CMRNG and ceftriaxone was 2 to 4 times as active as cefpodoxime weight for weight. Cefpodoxime may be a valuable additional oral agent for the treatment of gonorrhea in Australia. The sensitivity of gonococci to cefpodoxime can probably be inferred from values obtained for ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603756     DOI: 10.1080/00313029500169492

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

Review 1.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Authors:  Magnus Unemo; Daniel Golparian; Athena Limnios; David Whiley; Makoto Ohnishi; Monica M Lahra; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

3.  Cefpodoxime: pharmacokinetics and therapeutic uses.

Authors:  Krishan Chugh; Shruti Agrawal
Journal:  Indian J Pediatr       Date:  2003-03       Impact factor: 1.967

Review 4.  Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.

Authors:  Rui-xing Yu; Yueping Yin; Guan-qun Wang; Shao-chun Chen; Bing-jie Zheng; Xiu-qin Dai; Yan Han; Qi Li; Guo-yi Zhang; Xiangsheng Chen
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.